Multiple sclerosis treatment: First oral drug, new antibody therapies

JAAPA. 2011 Aug;24(8):54, 56. doi: 10.1097/01720610-201108000-00012.

Authors

Teresa Frohman¹, Megan Orchard, Paula Hardeman, Daniel L O'Donoghue

Affiliation

¹ Department of Neurology and Neurotherapeutics, The Clinical Center for Multiple Sclerosis, University of Texas Southwestern Medical Center, Dallas, USA.

PMID: 21850921
DOI: 10.1097/01720610-201108000-00012

No abstract available

MeSH terms

Administration, Oral
Antibodies, Monoclonal / therapeutic use*
Fingolimod Hydrochloride
Humans
Immunologic Factors / therapeutic use*
Multiple Sclerosis / drug therapy*
Propylene Glycols / therapeutic use*
Sphingosine / analogs & derivatives*
Sphingosine / therapeutic use

Substances

Antibodies, Monoclonal
Immunologic Factors
Propylene Glycols
Fingolimod Hydrochloride
Sphingosine